Ali Abdul Jabbar, MD
Interventional Cardiology · St Petersburg, FLNPI 1578729406
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $12,972 of the $15,107 with a category attached, or 85.9%. It is spread thinly across 36 manufacturers, the largest accounting for just 19.0% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2024 at $3,692 and has fallen 55.7% since, to $1,637 in 2025.
Across 332 payments — averaging $45.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$3K
- Edwards Lifesciences$2K
- Abbott$2K
- Shockwave Medical, Inc$1K
- Inari Medical, Inc.$1K
- Abiomed$1K
- plus $5K from 30 others
Across 7 payments — averaging $3363.20 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Cathworks, Inc.$22K
- Penumbra, Inc.$2K
What the payments were for
- Travel & lodging$2,13514%
- Food & beverage$12,97286%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 27 | $2,870 |
| Edwards Lifesciences | 20 | $2,271 |
| Abbott | 34 | $1,743 |
| Shockwave Medical, Inc | 36 | $1,206 |
| Inari Medical, Inc. | 9 | $1,190 |
| Abiomed | 25 | $1,094 |
| Cardiovascular Systems Inc. | 44 | $1,006 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 10 | $494 |
| Amgen | 24 | $375 |
| Endologix LLC | 1 | $326 |
| Philips North America LLC | 6 | $311 |
| Novartis | 19 | $275 |
| Boston Scientific | 6 | $268 |
| Pfizer | 16 | $253 |
| Johnson & Johnson | 7 | $217 |
| Reflow Medical Inc | 5 | $202 |
| AstraZeneca | 12 | $170 |
| W. L. Gore & Associates, Inc. | 1 | $127 |
| Alnylam Pharmaceuticals Inc. | 1 | $121 |
| Scpharmaceuticals Inc. | 4 | $93 |
| Merck | 4 | $78 |
| Lexicon Pharmaceuticals, Inc. | 3 | $67 |
| Boehringer Ingelheim | 3 | $51 |
| Cordis US CORP. | 2 | $46 |
| Kestra Medical Technology Services, Inc. | 1 | $34 |
| Regeneron Healthcare Solutions, Inc. | 1 | $30 |
| Kiniksa Pharmaceuticals, Ltd. | 2 | $27 |
| Actelion Pharmaceuticals US, Inc. | 1 | $25 |
| Chiesi USA, Inc. | 1 | $23 |
| Arbor Pharmaceuticals, Inc. | 1 | $21 |
| Novo Nordisk | 1 | $21 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $17 |
| Esperion Therapeutics, Inc. | 1 | $16 |
| Amarin Pharma, Inc. | 1 | $15 |
| Sanofi-aventis U.S. LLC | 1 | $12 |
| E.r. Squibb & Sons, L.L.C. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- COREVALVE EVOLUT R$1,391
- FLOWTRIEVER CATHETER, S$1,179
- Edwards SAPIEN 3 Transcatheter Heart Valve$1,077
- CT THROMBECTOMY SYSTEM KIT$773
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$564
- Impella$504
- Alto Abdominal Stent Graft System$326
- MitraClip$271
- CoreValve Evolut$261
- Diamondback Coronary$222
- IGT Devices Und$216
- NAVITOR$215
- Micra$163
- CARDIOMEMS$137
- LifeVest$135
- EXCLUDER Conformable AAA Endoprosthesis with Active Control$127
- SpiderFX$125
- Vascular Lithotripsy$124
- AMVUTTRA$121
- GENERAL - THERAPIES$118
How this compares
$15,107 in reported general payments places this provider in the 65th percentile of 623 interventional cardiology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 75 | $67,792 |
| FarxigaDapagliflozin Propanediol | 72 | $44,984 |
| JardianceEmpagliflozin | 29 | $22,334 |
| XareltoRivaroxaban | 15 | $19,788 |
| EntrestoSacubitril/Valsartan | 14 | $16,990 |
| MultaqDronedarone Hcl | 11 | $8,095 |
| Ranolazine ErRanolazine | 12 | $1,859 |
| Ezetimibe | 71 | $1,691 |
| Atorvastatin Calcium | 125 | $1,149 |
| Metoprolol Succinate | 92 | $1,044 |
| ClopidogrelClopidogrel Bisulfate | 91 | $942 |
| Torsemide | 42 | $622 |
| Rosuvastatin Calcium | 82 | $587 |
| Lisinopril | 77 | $519 |
| Potassium Chloride | 24 | $355 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $253 | $67,79275 claims |
| AstraZenecaFarxiga | $170 | $44,98472 claims |
| Boehringer IngelheimJardiance | $51 | $22,33429 claims |
| Johnson & JohnsonXarelto | $217 | $19,78815 claims |
| NovartisEntresto | $275 | $16,99014 claims |
| Sanofi-aventis U.S. LLCMultaq | $12 | $8,09511 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 623 interventional cardiology providers in Florida.
Other interventional cardiology in St Petersburg
- Arthur LeeGainesville$1.8M
- Santhosh MathewsBradenton$1.4M
- Siddharth WayangankarJacksonville$1.2M
- Patrick CambierTrinity$901K
- Zahid AminOrlando$635K
- Rohit AminPensacola$560K
- Eduardo de MarchenaMiami$498K
- Dominick AngiolilloJacksonville$387K
- Miguel DiazHialeah$383K
- Douglas EbersoleLakeland$373K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.